LH - OPKO Health gains after speculation on potential interest after GenMark deal

OPKO Health (OPK) rose 4.2% after a report speculated that the company could become a target following Roche's deal for GenMark Diagnostics (GNMK) and as OPKO is pressured by an activist holder.OPKO, which is seeing some pressure from investor Sian Capital to sell its BioReference Labs unit, may potentially see interest from Quidel (QDEL), which was reportedly in talks to do a transaction with Qiagen (QGEN), Dealreporter speculated today.Dealreporter also speculated Quest Diagnostics (DGX) and LabCorp (LH) could be potential buyers of OPKO's BioReference unit after Sian cited them as possible acquirers.Recall Feb. 24, LabCorp sum-of-the-parts worth $313/share with activist push, analyst says.

For further details see:

OPKO Health gains after speculation on potential interest after GenMark deal